Hematology News

The gap in cancer mortality between Black and white individuals shrunk dramatically during the past 3 decades, according to a new report.

The FDA’s decision to approve a one-time gene therapy for adults with moderate to severe hemophilia B could have a considerable impact on the treatment landscape, according to a researcher involved in the pivotal trial for the agent.

It is almost impossible to pick up a medical journal today without seeing an article or commentary on gene editing.

More than 20% of patients with cancer participate in some form of clinical study, and that number is considered a “floor” estimate, according to study results published in Journal of Clinical Oncology.

Among patients with congenital thrombotic thrombocytopenic purpura, prophylactic therapy with recombinant ADAMTS13 restored normal levels of the enzyme, according to results of a randomized phase 3 study.

The FDA approved fidanacogene elaparvovec-dzkt for treatment of adults with moderate to severe hemophilia B.

Many children with sickle cell anemia do not receive guideline-concordant preventive care to reduce their risks for serious infections or stroke, according to research conducted at Children’s Hospital Los Angeles.

Exagamglogene autotemcel gave most patients with beta-thalassemia transfusion independence and drastically reduced the number of vaso-occlusive crises in those with sickle cell disease in a pair of phase 3 trials.

Penumbra announced the FDA clearance and launch of its next-generation computer-assisted vacuum thrombectomy system to remove venous thrombus and treat pulmonary emboli.

An FDA advisory committee voted 12-2 that the benefits of the investigational therapy imetelstat outweigh the risks for the treatment of transfusion-dependent anemia in certain adults with myelodysplastic syndromes.